ES2095380T3 - Derivados de indano-2-carboxialquilo sustituidos en la posicion 2 utiles como inhibidores de la encefalinasa y la eca. - Google Patents

Derivados de indano-2-carboxialquilo sustituidos en la posicion 2 utiles como inhibidores de la encefalinasa y la eca.

Info

Publication number
ES2095380T3
ES2095380T3 ES92116264T ES92116264T ES2095380T3 ES 2095380 T3 ES2095380 T3 ES 2095380T3 ES 92116264 T ES92116264 T ES 92116264T ES 92116264 T ES92116264 T ES 92116264T ES 2095380 T3 ES2095380 T3 ES 2095380T3
Authority
ES
Spain
Prior art keywords
encephalinase
inhibitors
substituted
useful
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92116264T
Other languages
English (en)
Inventor
Alan W Warshawsky
Gary Alan Flynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2095380T3 publication Critical patent/ES2095380T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS DERIVADOS DE INDANO2-CARBOXIALKILO SUSTITUIDOS EN LA POSICION 2 UTILES COMO INHIBIDORES DE LA ENCEFALINASA Y DE LAS ACE.
ES92116264T 1991-09-27 1992-09-23 Derivados de indano-2-carboxialquilo sustituidos en la posicion 2 utiles como inhibidores de la encefalinasa y la eca. Expired - Lifetime ES2095380T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76728991A 1991-09-27 1991-09-27
US92948292A 1992-08-20 1992-08-20

Publications (1)

Publication Number Publication Date
ES2095380T3 true ES2095380T3 (es) 1997-02-16

Family

ID=27117892

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92116264T Expired - Lifetime ES2095380T3 (es) 1991-09-27 1992-09-23 Derivados de indano-2-carboxialquilo sustituidos en la posicion 2 utiles como inhibidores de la encefalinasa y la eca.

Country Status (15)

Country Link
EP (1) EP0534396B1 (es)
JP (1) JP3173674B2 (es)
KR (1) KR100271242B1 (es)
AT (1) ATE143972T1 (es)
AU (1) AU657793B2 (es)
CA (1) CA2079143C (es)
DE (1) DE69214397T2 (es)
DK (1) DK0534396T3 (es)
ES (1) ES2095380T3 (es)
FI (1) FI101302B (es)
GR (1) GR3021420T3 (es)
HU (1) HU214821B (es)
IL (1) IL103283A (es)
NO (1) NO300846B1 (es)
NZ (1) NZ244462A (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE155143T1 (de) * 1991-09-27 1997-07-15 Merrell Pharma Inc 2-substituierte indan-2-mercaptoacetylamid- verbindungen mit enkephalinase und ace- hemmwirkung
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
HUT71246A (en) * 1992-08-24 1995-11-28 Merrell Pharma Inc Mercaptoacylamine-substituted benzazepine derivatives condensed with heterocycles and process for preparing them
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
US5654294A (en) * 1993-05-13 1997-08-05 Bristol-Myers Squibb Spiro lactam dual action inhibitors
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
AU7186094A (en) * 1993-06-30 1995-01-24 Ciba-Geigy Ag Antihypertensive tricyclic azepine derivatives useful as inhibitors of enkephalinase and ace
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
CA2183313C (en) * 1994-02-14 2001-01-02 Gary A. Flynn Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
PT750631E (pt) * 1994-02-14 2000-07-31 Merrell Pharma Inc Novos derivados de dissulfureto de mercapto-aacetilamido-1,3,4,5-tetra-hidro-benzo¬c)azepin-3-ona uteis como inibidores de encefalinase e ace
JP3561753B2 (ja) * 1994-02-14 2004-09-02 メレル ファーマスーティカルズ インコーポレーテッド エンケファリナーゼ及びａｃｅの阻害剤として有用な、新規な２−置換インダン−２−メルカプトアセチルアミドジスルフィド誘導体類
US5616775A (en) * 1994-05-05 1997-04-01 Bristol-Myers Squibb Co. Process for preparing homocystein analogs useful as intermediates for compounds containing a fused bicyclic ring
CN1241924C (zh) * 1994-12-21 2006-02-15 阿温蒂斯药物公司 制备脑啡肽酶与血管紧张素转化酶抑制剂中间体的新方法及其中间体
US5641880A (en) * 1994-12-21 1997-06-24 Hoechst Marion Roussel, Inc. Processes for preparing intermediates of inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5877313A (en) 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
WO1999065500A1 (en) 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
KR20010085218A (ko) 1999-01-07 2001-09-07 구사마 사부로 잉크 리본 권취 기구를 구비한 프린터
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
HUP0203326A3 (en) 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
GB0119305D0 (en) 2001-04-12 2001-10-03 Aventis Pharma Gmbh Mercaptoacetylamide derivatives,a process for their preparation and their use
WO2003043624A1 (en) 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
EP2089355A2 (en) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
WO2008057855A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-i, and/or np-kappa-b activity
CN101573340A (zh) 2006-11-01 2009-11-04 百时美施贵宝公司 糖皮质激素受体AP-1和/或NF-κB活性的调节剂及其用途
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2065373A1 (de) 2007-11-30 2009-06-03 Bayer CropScience AG Chirale 3-(Benzylsulfinyl)-5,5-dimethyl-4,5-dihydroisoxazol-Derivate und 5,5-Dimethyl-3-[(1H-pyrazol-4-ylmethyl) sulfinyl]-4,5-dihydroisoxazol-Derivate, Verfahren zu deren Herstellung sowie deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
EP2065374A1 (de) 2007-11-30 2009-06-03 Bayer CropScience AG 2-(Benzyl- und 1H-pyrazol-4-ylmethyl)sulfinyl-Thiazol-Derivate als Herbizide und Pflanzenwachstumsregulatoren
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009158380A1 (en) 2008-06-24 2009-12-30 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8546377B2 (en) 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552889A (en) * 1983-06-09 1985-11-12 Eli Lilly And Company 3-Mercaptomethyl-2-oxo-1-pyrrolidine acetic acids and use for hypertension
CA1337654C (en) * 1986-06-13 1995-11-28 Gary A. Flynn Fused tricyclic lactams as antihypertensive agents
ZA874106B (en) * 1986-06-13 1987-12-08 Merrell Dow Pharmaceuticals Inc. Novel antihypertensive agent
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DK0492369T3 (da) * 1990-12-21 1997-10-13 Merrell Pharma Inc Hidtil ukendte tricycliske amino- og nitro-forbindelser med ACE-hæmmende virkning
ATE155143T1 (de) * 1991-09-27 1997-07-15 Merrell Pharma Inc 2-substituierte indan-2-mercaptoacetylamid- verbindungen mit enkephalinase und ace- hemmwirkung

Also Published As

Publication number Publication date
FI101302B1 (fi) 1998-05-29
KR930006028A (ko) 1993-04-20
JPH05230060A (ja) 1993-09-07
ATE143972T1 (de) 1996-10-15
FI101302B (fi) 1998-05-29
NZ244462A (en) 1994-08-26
EP0534396B1 (en) 1996-10-09
HU214821B (hu) 1998-06-29
FI924310A7 (fi) 1993-03-28
HU9203075D0 (en) 1992-12-28
FI924310A0 (fi) 1992-09-25
DE69214397T2 (de) 1997-03-06
NO300846B1 (no) 1997-08-04
DE69214397D1 (de) 1996-11-14
CA2079143A1 (en) 1993-03-28
NO923745L (no) 1993-03-29
HUT65278A (en) 1994-05-02
NO923745D0 (no) 1992-09-25
EP0534396A2 (en) 1993-03-31
DK0534396T3 (da) 1996-11-18
GR3021420T3 (en) 1997-01-31
IL103283A0 (en) 1993-02-21
KR100271242B1 (ko) 2001-02-01
EP0534396A3 (en) 1993-06-09
CA2079143C (en) 2004-03-16
AU2524692A (en) 1993-04-01
AU657793B2 (en) 1995-03-23
IL103283A (en) 1999-04-11
JP3173674B2 (ja) 2001-06-04

Similar Documents

Publication Publication Date Title
ES2114870T3 (es) Nuevos derivados de mercaptoacetilamida utiles como inhibidores de encefalinasa y eca.
ES2106112T3 (es) Derivados de indano-2-mercaptoacetilamida con una actividad inhibidora de encefalinasa y de ace.
ES2138622T3 (es) Derivados de mercaptoacetilamido piridazo(1,2-a)(1,2)diazepina utilizados como inhibidores de encefalinasa y eca.
HN1997000118A (es) 1,3, oxa thiolane nucleoside compuestos y composiciones
MX9300777A (es) Derivados aminoacetilmercapto novedosos utiles como inhibidores de la encefalinasa y la eca
IL103283A0 (en) Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
ES2155852T3 (es) Derivados de lactama biciclica de mercaptoacetilamida utiles como inhibidores de encefalinasa y eca.
DE69227574D1 (de) Massnahmen zur Verbesserung von Verstärkern
FI893618A7 (fi) Antibakteerisina aineina käyttökelpoisia amino-metyyliokso-oksatsolidinyyliaryylibentseeni-johdannaisia
HN1996000082A (es) Compuestos de quinolina y quinozssolina utiles en terapia.
FI942166L (fi) Menetelmiä restenoosin ehkäisemiseksi
FI962022L (fi) 5,6-dihydropyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina aineina
MX9302931A (es) Nuevas 4-aza-5&-colestan-onas 7b-substituidas como inhibidores de 5&-reductasa.
FI915783A7 (fi) N-jodipropargyylioksikarbonyyliaminohappoesterit ja niiden johdannaiset sekä niiden käyttö antimikrobisina aineina
MX9302116A (es) Compuestos azabiciclo.
FI962021L (fi) 5,6-dihydropyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina aineina
FI950842A7 (fi) Enkefalinaasin inhibiittoreina käyttökelpoisia uusia 2-substituoituja trisyklisiä indaani-2-merkaptoasetyyliamidijohdannaisia
YU48671B (sh) Novi derivati beta-fenilizoserina, njegovo dobijanje i primena
ES2042726T3 (es) Beta-alquilmelatoninas.
FI956151A7 (fi) Iskeemisissä taudeissa käyttökelpoisia bentseenijohdannaisia
FI894653A7 (fi) Stabiileja oksapeneemi-3-karboksyylihappoja ja niiden käyttö b-laktamaasin estäjinä
ES2089281T3 (es) Nuevos derivados de 2-mercaptometileno-tetrahidronaftaleno y 2-carboxamida indanos como inhibidores de la encefalinasa.
ATE131172T1 (de) Heterocyclische nmda antagonisten.
FI962020A7 (fi) Pyronijohdannaiset proteaasi-inhibiittoreina ja antiviraalisina ainein a
DE3650221D1 (de) Penemderivate.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 534396

Country of ref document: ES